Related Experiment Video
Updated: Jun 6, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
A decade of progress in lymphoma: advances and continuing challenges
Christopher R Flowers1, James O Armitage
1Lymphoma Program, Winship Cancer Institute, Emory University, 1365 Clifton Road, Atlanta, GA 30322, USA. crflowe@emory.edu
Clinical Lymphoma, Myeloma & Leukemia
|December 16, 2010
Summary
Advances in lymphoma treatment have improved survival for diffuse large B-cell lymphoma and follicular lymphoma. Further research into gene expression and peripheral T-cell lymphoma offers future treatment hope.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Significant progress in managing non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) over the last decade.
- Improved survival rates for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) due to rituximab incorporation.
- Gene expression profiling enhances lymphoma classification and treatment personalization.
Purpose of the Study:
- To review recent advancements in lymphoma management.
- To highlight disparities in treatment progress between B-cell and T-cell lymphomas.
- To identify future directions for improving peripheral T-cell lymphoma (PTCL) outcomes.
Main Methods:
- Review of current literature on lymphoma treatment and biology.
- Analysis of survival data and treatment efficacy for various lymphoma subtypes.
- Examination of gene expression patterns and their clinical relevance.
Main Results:
- Rituximab has significantly improved outcomes for DLBCL and FL.
- Hodgkin lymphoma management has advanced, with better identification of patients benefiting from less toxic therapies.
- Treatment progress for PTCL has lagged behind B-cell lymphomas.
Conclusions:
- Continued research into lymphoma biology and gene expression is crucial for personalized treatment.
- Developing targeted therapies and conducting specific clinical trials for PTCL are essential.
- Future efforts should focus on improving outcomes for aggressive PTCL subtypes.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Development of the Lymphatic System
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...